{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/chest-infections-adult/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"8d6a0737-dbc9-5f75-9d78-66599e03b11a","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field cb655c47-3a95-4cc5-a2c8-505d9e9b2e8c --><h2>Changes</h2><!-- end field cb655c47-3a95-4cc5-a2c8-505d9e9b2e8c -->","summary":null,"htmlStringContent":"<!-- begin item 063763c1-131a-4957-90cf-2efb8ff8c41a --><!-- begin field 54105645-c1fa-49e8-b959-8d47b24a4a92 --><p><strong>January 2021</strong> — minor update. Contraindications and drug interactions for erythromycin have been updated in line with an MHRA drug safety update. </p><!-- end field 54105645-c1fa-49e8-b959-8d47b24a4a92 --><!-- end item 063763c1-131a-4957-90cf-2efb8ff8c41a -->","topic":{"id":"ae03d3aa-8b14-5b48-b837-2390b93d3b8c","topicId":"473ddaff-d0fe-4ba6-950d-21174782d383","topicName":"Chest infections - adult","slug":"chest-infections-adult","lastRevised":"Last revised in January 2021","chapters":[{"id":"90a18d8c-865e-5bc5-b97d-7cc8e2e8b178","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e2a677e7-c782-5648-b8d3-af6f98f5ebf1","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"69d49ed5-19e9-5ca2-afb8-c08c815e9bd2","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8d6a0737-dbc9-5f75-9d78-66599e03b11a","slug":"changes","fullItemName":"Changes"},{"id":"4e71b8d1-9ea4-57ff-8862-79109a739b30","slug":"update","fullItemName":"Update"}]},{"id":"c97ad137-7a88-5cd3-8a35-9f8609bc27e3","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"c3eaa151-d5d8-59ae-82d9-c89db380b247","slug":"goals","fullItemName":"Goals"},{"id":"73a8fdad-99ee-5ab8-a499-cd210cbe2ea7","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f1989250-5170-573a-8d73-ccbd23325cc4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"698f6236-86b5-5358-b8f6-3d986ce6e62c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7998bfca-0c1f-51aa-874d-18dd62dc65b5","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"2547690c-ac67-5a70-874e-e724acc82aad","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b6392ff8-168f-5ece-b043-720dc73b7fdb","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"68203533-e202-5c04-b713-4d1f99e43d13","slug":"definition","fullItemName":"Definition"},{"id":"f05dcc7a-8622-5d0d-ba44-1a07f067c697","slug":"causes","fullItemName":"Causes"},{"id":"6dafb8b2-4871-5b47-ae51-7072fd0797ba","slug":"prevalence","fullItemName":"Prevalence"},{"id":"4f0c5b3d-3b3c-5c08-9f1d-f0fa9ed78995","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"dd5c4b0b-5449-5a20-b4b9-c1956ff731da","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"f8e2ad44-e229-588b-9421-5abb8d1366eb","slug":"assessment","fullItemName":"Assessment"},{"id":"8d401a7c-ada5-5bca-be9b-e0bde92f64d5","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"88bc2ad2-e15f-55af-a18a-db25d508dc89","fullItemName":"Management","slug":"management","subChapters":[{"id":"4ecbb38d-ec8f-5460-a468-aa870d049dfd","slug":"acute-bronchitis","fullItemName":"Scenario: Acute bronchitis"},{"id":"2afcbc23-a523-58d2-a490-ccfd81a2ce35","slug":"community-acquired-pneumonia","fullItemName":"Scenario: Community-acquired pneumonia"},{"id":"8782a14a-80d3-50d3-ab1b-9cc97e1fa22f","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"22189471-b7cd-534f-90d1-330da8d043b0","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"519bb329-75b0-5c14-84b8-9e6f162dcd2b","slug":"analgesia","fullItemName":"Analgesia"},{"id":"9e7786da-9ac8-50aa-bbac-6e15a0be127c","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"8cf724ea-6c07-5198-9916-b9d96d97acd2","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"4a74695a-622a-5bd3-b14f-cad47d602084","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"b500954c-b6b0-5e3b-ac55-0c2c6e2faf4c","slug":"erythromycin","fullItemName":"Erythromycin"}]},{"id":"8d0f9e0d-aea2-55e1-b4c1-b92b4c8161c4","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"96b9722b-40c5-5b7f-94ad-4223eb0a35e1","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"675135a4-558c-55ca-bcea-3c1d902517c3","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e36b3e2e-a318-543d-bec5-980aa965fcc6","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"0cdeaef3-f31b-5054-8e9e-7589311e7281","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"a75aec21-edc0-55f4-810d-3cf44899b423","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4085970a-642c-5d31-8c9f-414c768e84cb","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"76c4843c-7c5d-5f73-9c52-81b55b85ce03","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"69d49ed5-19e9-5ca2-afb8-c08c815e9bd2","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"6f20d0de-ba7f-5d84-893f-f23a8cd4b4a4","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 8274a43d-7e8d-4d1d-ade5-730065e06bbe --><h3>Previous changes</h3><!-- end field 8274a43d-7e8d-4d1d-ade5-730065e06bbe -->","summary":null,"htmlStringContent":"<!-- begin item 9cb69eb0-9f94-4dab-9b52-d26d4e0191d3 --><!-- begin field b9a745bc-dfeb-4535-9777-44b8a67aaddc --><p><strong>November 2020 </strong>— minor update. A new recommendation to consider VTE prophylaxis has been added to the management of community-acquired pneumonia. </p><p><strong>May 2020 </strong>— minor update. Links to the COVID-19 management scenario have been added in the Assessment section and the Management of community-acquired pneumonia section to highlight that assessment of suspected chest infection and management of community-acquired pneumonia will differ during the COVID-19 pandemic. </p><p><strong>April 2020 </strong>— minor update. New management scenario created to provide information regarding COVID-19. </p><p><strong>July to September 2019 </strong>— reviewed. A literature search was conducted in May 2019 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials (RCTs) published since the last revision of the topic. </p><p>Recommendations on the management, follow up, and referral of acute bronchitis and community-acquired pneumonia have been added and amended in line with the 2019 National Institute for Health and Care Excellence guidelines on <em>Cough (acute): antimicrobial prescribing </em>and <em>Pneumonia (community-acquired): antimicrobial prescribing.</em> Prescribing information has been adjusted to reflect these recommendations, including the addition of a section on erythromycin. </p><p><strong>September to November 2015 </strong>— reviewed. A literature search was conducted in September 2015 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials (RCTs) published since the last revision of the topic. No major changes to clinical recommendations have been made.</p><p><strong>July 2015</strong> — minor update. Information on the concurrent use of clarithromycin with statins has been clarified.</p><p><strong>April 2015</strong> — minor update. The prescribing information on analgesia has been replaced with a link to the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/\">Analgesia - mild-to-moderate pain</a>. </p><p><strong>December 2014</strong> — minor update. Additional information regarding the contraindication of clarithromycin and lovastatin or simvastatin. </p><p><strong>February 2013</strong> — minor update. The 2013 QIPP options for local implementation have been added to this topic. </p><p><strong>October 2012</strong> — minor update. The 2012 QIPP options for local implementation have been added to this topic. </p><p><strong>May to July 2012</strong> — reviewed. A literature search was conducted in April 2012 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of the topic. No major changes to clinical recommendations have been made.</p><p><strong>May 2011</strong> — minor update. The 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011. </p><p><strong>October 2010</strong> — technical update. The management section of this topic has been simplified to improve clarity and navigation. There have been no changes to the clinical content or meaning of the recommendations. </p><p><strong>September 2010</strong> — minor update. The Supporting evidence on a delayed antibiotic prescribing strategy compared with a no antibiotic prescribing strategy has been updated. Issued in September 2010. </p><p><strong>October 2009</strong> — updated to include the BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Issued in November 2009. </p><p><strong>April 2009</strong> — minor update. Dose of erythromycin in the Prescriptions section in the scenario Acute bronchitis has been corrected. Issued in May 2009. </p><p><strong>January 2009</strong> — minor update. Minor change in wording regarding when to prescribe doxycycline, erythromycin, and clarithromycin, in line with updated advice from the Health Protection Agency. Issued in February 2009. </p><p><strong>May to August 2007</strong> — converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. This CKS topic replaces the CKS guidance on Chest infections, together with the CKS topic on Cough - acute with chest signs in children. Advice on the management of acute exacerbations in chronic obstructive pulmonary disease has been removed and can now be found in the CKS topic on Chronic obstructive pulmonary disease. Prescriptions for oxytetracycline and for flucloxacillin have been removed. </p><p><strong>October 2006</strong> — minor update. Analgesia prescriptions updated because new doses of ibuprofen for children are recommend by the British National Formulary. Issued in October 2006. </p><p><strong>October 2005</strong> — minor update. Volumatic® spacer device discontinued and prescriptions removed; advice for using alternative spacer devices included. Issued in November 2005. </p><p><strong>July 2005</strong> — updated to incorporate the Referral guidelines for suspected cancer published by the National Institute for Health and Clinical Excellence. Issued in July 2005. </p><p><strong>March 2004</strong> — reviewed. Validated in May 2004 and issued in July 2004.</p><p><strong>March 2001</strong> — reviewed. Validated in July 2001 and issued in October 2001.</p><p><strong>June 1998</strong> — written.</p><!-- end field b9a745bc-dfeb-4535-9777-44b8a67aaddc --><!-- end item 9cb69eb0-9f94-4dab-9b52-d26d4e0191d3 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}